August 6, 2013
SIU Med School Part of National Alzheimer’s Disease Study
Individuals who are diagnosed with Alzheimer’s disease who exhibit anger and aggression may be eligible to participate in a national multi-site study of the drug ELND005 at Southern Illinois University School of Medicine. The drug is being evaluated for the treatment of agitation and aggression in patients with moderate Alzheimer’s disease.
"This drug will hopefully reduce the outbursts of anger, aggression and agitation that many people with Alzheimer’s disease experience," said Dr. Tom Ala, associate professor of neurology and interim director of the Center for Alzheimer’s Disease and Related Disorders at SIU, who is principal investigator for the study.
Volunteers must be between the ages of 50 and 85 and have been diagnosed with moderate to severe Alzheimer’s disease. They must exhibit agitation and aggression at least once a week, and be on stable doses of symptomatic AD drugs.
Each participant will receive physical and neurological examinations and other tests prior to the pharmaceutical trial starting date and during four follow-up visits over three months. Participants of the trial are not charged for the tests and medications related to the study, which is sponsored by Elan Pharma.
Anyone interested in participating in the study should contact Barbara Lokaitis at email@example.com or call 217-545-9737 weekdays.